1-3 of 3
Luomengjia Dai
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Exploration of the Specific Mechanism of EGR2 Hotspot Mutation Mediating the Upregulation of Galectin-1 Expression in the Progression of CLL Following Treatment with BTK Inhibitor

Xiao Lu, Yeqin Sha, Xinyu Song, Luomengjia Dai, Ziyuan Zhou, Hanning Tang, Yi Miao, Shuchao Qin, Yi Xia, Tonglu Qiu, Lei Fan, Jianyong Li, Huayuan Zhu
Journal: Blood
Blood (2024) 144 (Supplement 1): 4612.
https://doi.org/10.1182/blood-2024-207729
Published: 2024
Journal Articles

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)

Huayuan Zhu, Yi Miao, Shuchao Qin, Ming Liu, Yi Xia, Luomengjia Dai, Tonglu Qiu, Chong-Yang Ding, Hairong Qiu, Chun Qiao, Yujie Wu, Fei Li, Xiao Lu, Wei Xu, Lei Fan, Jianyong Li
Journal: Blood
Blood (2024) 144 (Supplement 1): 3244.
https://doi.org/10.1182/blood-2024-204881
Published: 2024
Journal Articles

A Single Center Real World Study of Outcome and Resistance of Bruton Tyrosine Kinase Inhibitors (BTKi) in Chinese Patients with Chronic Lymphocytic Leukeima/Small Lymphocytic Lymphoma

Huayuan Zhu, Luomengjia Dai, Yeqin Sha, Xiao Lu, Siqi Qian, Tonglu Qiu, Yi Miao, Yi Xia, Shuchao Qin, Ziyuan Zhou, Wei Wu, Lei Fan, Wei Xu, Jianyong Li
Journal: Blood
Blood (2023) 142 (Supplement 1): 4653.
https://doi.org/10.1182/blood-2023-189681
Published: 2023